Leadership & Pay ·
Aardvark Therapeutics held its Annual Meeting on August 14, 2026, with 54.79% of outstanding shares voting
AARDAardvark Therapeutics, Inc.
Aardvark Therapeutics held its Annual Meeting on August 14, 2026, with 54.79% of outstanding shares voting. Stockholders elected Victor Tong, Jr. and Jeffrey Chi as Class I directors and ratified BDO USA, P.C. as the independent auditor. Crucially, shareholders approved the repricing of certain outstanding stock options under the Company's equity incentive plans. This corporate action modifies existing compensation agreements for eligible participants. Aardvark Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.